MCID: OST115
MIFTS: 38

Osteonecrosis of the Jaw malady

Categories: Bone diseases, Rare diseases, Oral diseases

Aliases & Classifications for Osteonecrosis of the Jaw

Aliases & Descriptions for Osteonecrosis of the Jaw:

Name: Osteonecrosis of the Jaw 56

Classifications:



External Ids:

Orphanet 56 ORPHA399293
ICD10 via Orphanet 34 K10.2

Summaries for Osteonecrosis of the Jaw

MalaCards based summary : Osteonecrosis of the Jaw is related to rheumatoid arthritis and osteonecrosis. An important gene associated with Osteonecrosis of the Jaw is CYP2C8 (Cytochrome P450 Family 2 Subfamily C Member 8), and among its related pathways/superpathways are Allograft rejection and HTLV-I infection. The drugs Alendronate and Zoledronic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and breast.

Wikipedia : 71 Osteonecrosis of the jaw (ONJ) is a severe bone disease (osteonecrosis) that affects the jaws (the... more...

Related Diseases for Osteonecrosis of the Jaw

Diseases related to Osteonecrosis of the Jaw via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 72)
id Related Disease Score Top Affiliating Genes
1 rheumatoid arthritis 30.0 HLA-DQB1 HLA-DRB1 IL17A VEGFA
2 osteonecrosis 11.0
3 osteoporosis 10.3
4 multiple myeloma 10.2
5 apple allergy 10.2 HLA-DQB1 HLA-DRB1
6 hemoglobin d disease 10.2 HLA-DQB1 HLA-DRB1
7 bilateral parasagittal parieto-occipital polymicrogyria 10.2 HLA-DQB1 HLA-DRB1
8 immune deficiency, familial variable 10.2 HLA-DQB1 HLA-DRB1
9 lin-gettig syndrome 10.2 HLA-DQB1 HLA-DRB1
10 midline interhemispheric variant of holoprosencephaly 10.2 HLA-DQB1 HLA-DRB1
11 autosomal dominant intermediate charcot-marie-tooth 10.2 HLA-DQB1 HLA-DRB1
12 renal agenesis meningomyelocele mullerian defect 10.2 HLA-DQB1 HLA-DRB1
13 lyme disease - neurological complications 10.2 HLA-DQB1 HLA-DRB1
14 distal trisomy 14q 10.2 HLA-DQB1 HLA-DRB1
15 learning disability 10.2 HLA-DQB1 HLA-DRB1
16 reproductive system disease 10.2 HLA-DRB1 IL17A
17 linear lichen planus 10.2 HLA-DQB1 HLA-DRB1
18 night blindness 10.2 HLA-DQB1 HLA-DRB1
19 cervical adenoid basal carcinoma 10.2 HLA-DQB1 HLA-DRB1
20 clostridium difficile colitis 10.2 HLA-DQB1 HLA-DRB1
21 myofibroma 10.1 HLA-DQB1 HLA-DRB1
22 pancreas adenocarcinoma 10.1 CYP2C8 FDPS VEGFA
23 oromandibular dystonia 10.1 HLA-DQB1 HLA-DRB1
24 anaerobic meningitis 10.1 HLA-DQB1 HLA-DRB1 VEGFA
25 arthritis 10.1
26 periodontitis 10.1
27 cryptococcosis 10.1 HLA-DQB1 HLA-DRB1 IL17A
28 anterior corneal pigmentation 10.1 HLA-DQB1 HLA-DRB1 IL17A
29 prostate disease 10.1 DEFB1 VEGFA
30 bowman's membrane folds or rupture 10.1 DEFB1 DEFB4A
31 bickerstaff brainstem encephalitis 10.0 HLA-DQB1 HLA-DRB1
32 advanced sleep phase syndrome, familial, 1 10.0 HLA-DQB1 HLA-DRB1 IL17A
33 breast cancer 10.0
34 prostatitis 10.0
35 thrombophilia 10.0
36 periodontal disease 10.0
37 gonadal disease 10.0 DEFB1 DEFB4A
38 histiocytosis 10.0 DEFB1 DEFB4A IL17A
39 intratubular embryonal carcinoma 10.0 DEFB1 DEFB4A IL17A
40 autistic disorder 9.9 HLA-DQB1 HLA-DRB1 IL17A
41 sclerosing cholangitis 9.9 DEFB1 DEFB4A
42 periventricular leukomalacia 9.9 DEFB4A IL17A
43 fibrous dysplasia 9.9
44 prostate cancer 9.9
45 osteomyelitis 9.9
46 endotheliitis 9.9
47 hepatitis 9.9
48 lung cancer 9.7
49 fasciitis 9.7
50 necrotizing fasciitis 9.7

Graphical network of the top 20 diseases related to Osteonecrosis of the Jaw:



Diseases related to Osteonecrosis of the Jaw

Symptoms & Phenotypes for Osteonecrosis of the Jaw

Drugs & Therapeutics for Osteonecrosis of the Jaw

Drugs for Osteonecrosis of the Jaw (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4,Phase 2 121268-17-5, 66376-36-1 2088
2
Zoledronic acid Approved Phase 4,Phase 3 118072-93-8 68740
3 Diphosphonates Phase 4,Phase 3,Phase 1
4 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Hormones Phase 4
6
Gemcitabine Approved Phase 3 95058-81-4 60750
7
Denosumab Approved Phase 3,Phase 1 615258-40-7
8
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
9
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
10
Docetaxel Approved May 1996, Investigational Phase 3 114977-28-5 148124 9877265
11 Trace Elements Phase 3,Phase 2
12 Vitamins Phase 3,Phase 2,Phase 1
13 Micronutrients Phase 3,Phase 2
14 Ibandronic acid Phase 3
15 Tocopherols Phase 3
16 Tocotrienols Phase 3
17 Vasodilator Agents Phase 3
18 Phosphodiesterase Inhibitors Phase 3
19 Platelet Aggregation Inhibitors Phase 3
20 Protective Agents Phase 3
21 Radiation-Protective Agents Phase 3
22 Antioxidants Phase 3
23 Tocopherol Nutraceutical Phase 3
24 Tocotrienol Nutraceutical Phase 3
25
Calcium carbonate Approved Phase 2 471-34-1
26
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
27 vitamin d Phase 2,Phase 1
28 Gastrointestinal Agents Phase 2
29 Antacids Phase 2
30 Ergocalciferols Phase 2
31 Anti-Ulcer Agents Phase 2
32 Calcium, Dietary Phase 2,Phase 1
33 Vitamin D2 Nutraceutical Phase 2
34 Calciferol Nutraceutical Phase 2
35
Amoxicillin Approved, Vet_approved 26787-78-0 33613 2171
36
Menthol Approved 2216-51-5 16666
37
Pamidronate Approved 40391-99-9 4674
38
Etidronic acid Approved 7414-83-7, 2809-21-4 3305
39
tiludronate Approved, Vet_approved 89987-06-4 60937
40
Sunitinib Approved, Investigational 341031-54-7, 557795-19-4 5329102
41
Miconazole Approved, Investigational, Vet_approved 22916-47-8 4189
42
Teriparatide Approved, Investigational 52232-67-4 16133850
43
Cholecalciferol Approved, Nutraceutical 67-97-0 6221 10883523 5280795
44 Clavulanic Acid
45 Mitogens
46 Amoxicillin-Potassium Clavulanate Combination
47 Anti-Bacterial Agents
48 beta-Lactamase Inhibitors
49 Anti-Infective Agents
50 Antibiotics, Antitubercular

Interventional clinical trials:

(show all 31)
id Name Status NCT ID Phase
1 Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis Unknown status NCT00265252 Phase 4
2 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4
3 Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study Completed NCT02139007 Phase 4
4 Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial Completed NCT02181101 Phase 3
5 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks Recruiting NCT02051218 Phase 3
6 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Active, not recruiting NCT00869206 Phase 3
7 Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ) Not yet recruiting NCT03040778 Phase 3
8 Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma Terminated NCT02739594 Phase 3
9 Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents Completed NCT00921557 Phase 2
10 Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates Completed NCT00462098 Phase 1
11 Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis Recruiting NCT02566681 Phase 1
12 Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children Not yet recruiting NCT02677246 Phase 1
13 Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay Unknown status NCT02218554
14 Prospective Randomized Study: Assessment of PRF Efficacy in Prevention of Jaw Osteonecrosis After Tooth Extraction Unknown status NCT02198001
15 CONDOR Study of Osteonecrosis of the Jaws (TMJ) Completed NCT01130389
16 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer Completed NCT01325142
17 Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw Completed NCT01998607
18 DPBRN Retrospective Cohort Study of Osteonecrosis of the Jaw Completed NCT01201330
19 Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis Completed NCT00601068
20 Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging Completed NCT00592982
21 Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC Completed NCT01062503
22 Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use Recruiting NCT01875458
23 Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction Recruiting NCT02661139
24 HBOT Late Radiation Tissue Injury Recruiting NCT02425215
25 Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques Recruiting NCT02747173
26 Osteonecrosis of the Jaw (ONJ) Case Registry Active, not recruiting NCT01666106
27 Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid Active, not recruiting NCT01967160
28 S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Active, not recruiting NCT00874211
29 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study Active, not recruiting NCT00858585
30 Medication-related Osteonecrosis of the Jaw (MRONJ) Registry Not yet recruiting NCT02932501
31 Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid Withdrawn NCT02069340

Search NIH Clinical Center for Osteonecrosis of the Jaw

Genetic Tests for Osteonecrosis of the Jaw

Anatomical Context for Osteonecrosis of the Jaw

MalaCards organs/tissues related to Osteonecrosis of the Jaw:

39
Bone, T Cells, Breast, Prostate, Endothelial, Kidney, Myeloid

Publications for Osteonecrosis of the Jaw

Articles related to Osteonecrosis of the Jaw:

(show top 50) (show all 362)
id Title Authors Year
1
Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. ( 27856150 )
2017
2
Histochemical observation of bony reversal lines in bisphosphonate-related osteonecrosis of the jaw. ( 27989705 )
2017
3
High frequency of osteonecrosis of the jaw among denosumab-treated prostate cancer patients. ( 27921521 )
2017
4
Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphosphonates. ( 27918742 )
2017
5
Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review. ( 27876532 )
2017
6
The starting point for bisphosphonate-related osteonecrosis of the jaw: Alveolar bone or oral mucosa? A randomized, controlled experimental study. ( 27919595 )
2017
7
Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents. ( 27046950 )
2016
8
Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates. ( 27866217 )
2016
9
Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis? ( 27092912 )
2016
10
Resection and microvascular reconstruction of bisphosphonate-related osteonecrosis of the jaw: The role of microvascular reconstruction. ( 27159622 )
2016
11
Medication-related osteonecrosis of the jaw associated with aflibercept. ( 27923511 )
2016
12
Cast-cap splint in the management of medication-related osteonecrosis of the jaw. ( 28017378 )
2016
13
Discrepancy between long-term and previously published analysis for osteonecrosis of the jaw under denosumab. ( 27121570 )
2016
14
Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. ( 27956123 )
2016
15
Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws. ( 27591091 )
2016
16
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. ( 27079903 )
2016
17
Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database. ( 27179251 )
2016
18
Acute Generalized Exanthematous Pustulosis Due to Labetalol; Drug Fever and Leukocytosis Caused by Tigecycline; Toxic Hepatitis Induced by Methylprednisolone Intravenous Pulse Dosing; Mitoxantrone-Related Osteonecrosis of the Jaw; Medications with Anticholinergic Effects and Their Implications in the Elderly. ( 27354743 )
2016
19
Spontaneous Osteonecrosis of the Jaw During Bisphosphonate Therapy: An Unusual Etiology of the Numb Chin Syndrome. ( 27491573 )
2016
20
Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): a systematic review. ( 27025860 )
2016
21
Extensive Surgical Procedures Result in Better Treatment Outcomes for Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Osteoporosis. ( 28039736 )
2016
22
Adjusted protocol for dental extractions in oncology patients taking anti-resorptive drugs may reduce occurrence of medication-related osteonecrosis of the jaw. ( 27012569 )
2016
23
Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw. ( 27847735 )
2016
24
Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw. ( 27137436 )
2016
25
Photodynamically dealing with bisphosphonate-related osteonecrosis of the jaw: successful case reports. ( 27585753 )
2016
26
Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I. ( 27501591 )
2016
27
Short-term perioperative teriparatide therapy for the prevention of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats. ( 28087282 )
2016
28
Osteonecrosis of the Jaw-a Bone Site-Specific Effect of Bisphosphonates. ( 27474028 )
2016
29
Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. ( 27862983 )
2016
30
Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702. ( 27928641 )
2016
31
Therapeutic interactions between mesenchymal stem cells for healing medication-related osteonecrosis of the jaw. ( 27530108 )
2016
32
Clinical features of peri-implant medication-related osteonecrosis of the jaw: Is there an association to peri-implantitis? ( 27836551 )
2016
33
Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity. ( 27167455 )
2016
34
Retrospective Audit: Does Prior Assessment by Oral and Maxillofacial Surgeons Reduce the Risk of Osteonecrosis of The Jaw in Patients Receiving Bone-Targeted Therapies for Metastatic Cancers to the Skeleton?--Part II. ( 27501592 )
2016
35
Plasticity of Myeloid Cells during Oral Barrier Wound Healing and the Development of Bisphosphonate-related Osteonecrosis of the Jaw. ( 27514746 )
2016
36
Bisphosphonate-related osteonecrosis of the jaw: a review of the potential efficacy of low-level laser therapy. ( 27029476 )
2016
37
Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. ( 27475683 )
2016
38
A 5-year perspective on a removable overdenture appliance for a patient with osteonecrosis of the jaw, a mandibular resection, and rampant caries. ( 26996932 )
2016
39
Tetraparesis after surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: a case report. ( 27057695 )
2016
40
Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. ( 27651287 )
2016
41
Medication-related osteonecrosis of the jaw: a dentist's nightmare. ( 27053542 )
2016
42
Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. ( 28035494 )
2016
43
Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case. ( 27648313 )
2016
44
Prevalence of osteonecrosis of the jaw and oral characteristics of oncologic patients treated with bisphosphonates at the General Hospital of Mexico. ( 28053907 )
2016
45
IL-36 Induces Bisphosphonate-Related Osteonecrosis of the Jaw-Like Lesions in Mice by Inhibiting TGF-I^-Mediated Collagen Expression. ( 27567012 )
2016
46
Design and methods for a Scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events. ( 27499646 )
2016
47
A Strategy against the Osteonecrosis of the Jaw Associated with Nitrogen-Containing Bisphosphonates (N-BPs): Attempts to Replace N-BPs with the Non-N-BP Etidronate. ( 27582334 )
2016
48
Osteonecrosis of the jaw associated with ziv-aflibercept. ( 28078129 )
2016
49
Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw. ( 27519659 )
2016
50
Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw? ( 28042979 )
2016

Variations for Osteonecrosis of the Jaw

Expression for Osteonecrosis of the Jaw

Search GEO for disease gene expression data for Osteonecrosis of the Jaw.

Pathways for Osteonecrosis of the Jaw

GO Terms for Osteonecrosis of the Jaw

Cellular components related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transport vesicle membrane GO:0030658 9.32 HLA-DQB1 HLA-DRB1
2 clathrin-coated endocytic vesicle membrane GO:0030669 9.26 HLA-DQB1 HLA-DRB1
3 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.16 HLA-DQB1 HLA-DRB1
4 MHC class II protein complex GO:0042613 8.96 HLA-DQB1 HLA-DRB1
5 Golgi lumen GO:0005796 8.8 DEFB1 DEFB103B DEFB4A

Biological processes related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.58 DEFB1 DEFB103B DEFB4A
2 defense response GO:0006952 9.54 DEFB1 DEFB103B DEFB4A
3 immune response GO:0006955 9.35 DEFB1 DEFB4A HLA-DQB1 HLA-DRB1 IL17A
4 antimicrobial humoral response GO:0019730 9.33 DEFB1 DEFB103B DEFB4A
5 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.32 HLA-DQB1 HLA-DRB1
6 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.26 HLA-DQB1 HLA-DRB1
7 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.62 HLA-DQB1 HLA-DRB1

Molecular functions related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxygen binding GO:0019825 9.32 CYP19A1 CYP2C8
2 peptide antigen binding GO:0042605 9.26 HLA-DQB1 HLA-DRB1
3 aromatase activity GO:0070330 9.16 CYP19A1 CYP2C8
4 MHC class II receptor activity GO:0032395 8.96 HLA-DQB1 HLA-DRB1
5 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB1 DEFB4A

Sources for Osteonecrosis of the Jaw

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....